BioPharma Dive November 18, 2021
Diabetes drug specialist Novo Nordisk has agreed to acquire Dicerna Pharmaceuticals in a deal worth $3.3 billion, a strategic bet that an existing wide-ranging alliance between the two will yield multiple medicines for a range of diseases.
Novo will pay $38.25 per share in cash for Dicerna, an 80% premium to the $21.28 closing price of the biotech’s shares Wednesday — the third-highest premium in a deal for a publicly traded biotech this year, according to BioPharma Dive’s database. The boards of both companies have unanimously approved the deal, which is expected to close in the fourth quarter.
For Novo, the buyout is well-timed. Shares in Dicerna are trading near their lowest price in the past year, largely due to...
Today's Sponsors
Today's Sponsor